Top 10 Evidence-Based Essentials in Family Medicine - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Top 10 Evidence-Based Essentials in Family Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

  • By

  • mdspire news news staff

  • May 27, 2026

  • 3 min

Share

Clinical Scorecard: Top 10 Evidence-Based Essentials in Family Medicine

At a Glance

CategoryDetail
ConditionFamily Medicine
Key MechanismsPreventive care guidelines, chronic disease management, screening tools
Target PopulationPatients aged 19 years and older
Care SettingPrimary care

Key Highlights

  • SELECT trial

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • t
    • h
    • e
    • n
    • o
    • t
    • e
    • o
    • n
    • i
    • n
    • s
    • u
    • f
    • f
    • i
    • c
    • i
    • e
    • n
    • t
    • e
    • v
    • i
    • d
    • e
    • n
    • c
    • e
    • f
    • o
    • r
    • p
    • a
    • t
    • i
    • e
    • n
    • t
    • s
    • a
    • g
    • e
    • d
    • 7
    • 6
    • y
    • e
    • a
    • r
    • s
    • o
    • r
    • o
    • l
    • d
    • e
    • r
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Add trial names for dapagliflozin and empagliflozin findings.

        Clinical Best Practices

        • Incorporate shared clinical decision-making in vaccine recommendations.
        • Utilize validated screening tools for mental health assessment.

        Related Resources & Content

        Original Source(s)

        Top 10 Evidence-Based Essentials in Family Medicine

        • by mdspire news news staff

        • May 27, 2026

        Related Content

        Can SGLT2 Inhibitors Affect Dementia?

        A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.

        FDA Grants Traditional Approval to Iptacopan in Primary IgAN

        Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

        Daily Itch Duration Linked to Quality-of-Life Burden

        Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.